Posted On: 03/17/2015 11:02:29 AM
Post# of 99250
There are 2 major takeaways investors should monitor based on this news:
1. The Establishment Labs option essentially values VTEQD's breast implant marker business at $10 Million dollars, with the current market cap around $40k, this would have VeriTeQ severely undervalued by the market.
2. Perhaps even more interesting, is the fact that we have yet to hear about Mentor or Allergen on this matter. These companies together represent 81% of the breast implant market, and currently have no competing technologies in development. Knowing the FDA's new requirements, as well as the cost associated with developing a technology like VeriTeQ's, it would seem logical that VeriTeQ could begin to receive interest from these major players in the implantation market."
http://finance.yahoo.com/news/ticker-research...00991.html
1. The Establishment Labs option essentially values VTEQD's breast implant marker business at $10 Million dollars, with the current market cap around $40k, this would have VeriTeQ severely undervalued by the market.
2. Perhaps even more interesting, is the fact that we have yet to hear about Mentor or Allergen on this matter. These companies together represent 81% of the breast implant market, and currently have no competing technologies in development. Knowing the FDA's new requirements, as well as the cost associated with developing a technology like VeriTeQ's, it would seem logical that VeriTeQ could begin to receive interest from these major players in the implantation market."
http://finance.yahoo.com/news/ticker-research...00991.html
(0)
(0)
